HOW LOCAL treatment of ulcerative gastroduodenal hemorrhage ASSOCIATED WITH H. pylori infection

摘要

1.a local u043bu0435u0447u0435u043du0438u00a0 u00a0u0437u0432u0435u043du043du044bu0445 u0433u0430u0441u0442u0440u043eu0434u0443u043eu0434u0435u043du0430u043bu044cu043du044bu0445 bleeding associated with u0445u0435u043bu0438u043au043eu0431u0430u043au0442u0435u0440u043du043eu0439 infection, including the introduction of drugs in u0431u043bu0430u0441u0442u044c u00a0u0437u0432u0435u043du043du043eu0433u043e defect in the u0444u0438u0431u0440u043eu0433u0430u0441u0442u0440u043eu0434u0443u043eu0434u0441u043du043eu0441u043au043eu043fu0438u0438, u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 orderagainst the backdrop of u0430u043du0442u0438u0445u0435u043bu0438u043au043eu0431u0430u043au0442u0435u0440u043du043eu0439 therapy consistently u043fu0440u043eu0432u043eu0434u00a0u0442 several adhesive applications, by simultaneously u0432u0432u0435u0434u0435u043du0438u00a0 medicines with u0430u044du0440u043eu0437u043eu043bu044cu043d ies of glue, u0441u043eu0437u0434u0430u0432u0430u00a0 in u00a0u0437u0432u0435u043du043du043eu0433u043e defect area of high concentration of drugs and their u043fu0440u043eu043bu043eu043du0433u0438u0440u043eu0432u0430u043du043du043eu0435 effect.;2. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1, so that the u0430u043du0442u0438u0445u0435u043bu0438u043au043eu0431u0430u043au0442u0435u0440u043du0430u00a0 u0442u0435u0440u0430u043fu0438u00a0 includes receiving ranitidine in a dose of 150 mg twice a day in combination with u0442u0435u0442u0440u0430u0446u0438u043au043bu0438u043du043eu043c u0433u0438u0434u0440u043eu0445u043bu043eu0440u0438u0434u0430 on 500 mg four times a day and u043cu0435u0442u0440u043eu043du0438u0434u0430u0437u043eu043bu043eu043c 500 mg two times a day for 2 to 3 weeks.;3. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1, so that the first glue application as a drug vehicle use 400 iu. u0442u0440u043eu043cu0431u0438u043du0430, divorced in 1.5 ml physiological saline.;4. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1 or 3, 12, 24 h u043fu0440u043eu0432u043eu0434u00a0u0442 another adhesive own application, as well as drug vehicles using 0.5 g venter, u0440u0430u0437u0432u0435u0434u0435u043du043du043e in 1 ml of 1% solution of t u0430u043au0442u0438u0432u0438u043du0430.;5. way on any of the u043fu043f.1, 3 and 4, u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0, 3 to 4 u0434u043du00a0 u043fu0440u043eu0432u043eu0434u00a0u0442 next adhesive own application, as well as drug vehicles using 0.5 g u043cu0435u0442u0438u043bu0443u0440 u0430u0446u0438u043bu0430, divorced in 1 ml of 1% solution of t u0430u043au0442u0438u0432u0438u043du0430.;6. method for u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0 1, so that, in the case of relapse u043au0440u043eu0432u043eu0442u0435u0447u0435u043du0438u00a0 the glue application u043fu043eu0432u0442u043eu0440u00a0u044eu0442.